C278 Haematex new

DOAC removal tablets

DOAC-Stop removes all types of Direct Oral Anti-Coagulants (DOACs; dabigatran, apixaban, rivaroxaban, and edoxaban, etc) from test plasmas with minimal effect on underlying blood clotting tests. The simple procedure involves adding one mini-tablet per 1ml test plasma (volume is not critical), mixing for 5 minutes and centrifuging down the adsorbent. The resulting plasma is then depleted of DOACs and yields similar APTT, dRVVT, PT(INR) and other results as if DOACs had not been present. Reversing agents coming into therapeutic use for individual DOACs are not widely available for lab tests. DOAC-Stop is now offered for simplifying the diagnostic problems associated with DOACs. It absorbs up to an estimated 2,000ng/ml of any DOAC in less than 5 minutes. Unlike therapeutic  additives for reversing DOACs it leaves no residual effect. It can be used for checking if DOACs are present in samples giving unexpectedly prolonged clotting test or abnormal chromogenic test results. There is negligible interference with vitamin K antagonist or heparinoid anticoagulants. Plasmas treated with DOAC-Stop can be used for valid factor assays and in testing for thrombotic risk. In particular it can prevent false LAC positive results due to DOACs or other agents in testing for lupus anticoagulants. The product is currently for research use only.

Supplier: Haematex Research Pty Ltd

Mail the supplier